Kelun-Biotech sac-TMT plus Keytruda posts 51% ORR in cervical cancer trial cohort

• Kelun-Biotech disclosed Phase II SKB264-II-06/MK-2870-002 results for TROP2 ADC sacituzumab tirumotecan (Sac-TMT) with Merck’s pembrolizumab in ovarian cancer, cervical cancer.
• Data were presented at 2026 Society of Gynecologic Oncology Annual Meeting, based on analyses cut off Nov. 17, 2025.
• Ovarian cancer cohort showed treatment extended disease control in maintenance setting for BRCA wild-type, second-line platinum-sensitive recurrent disease.
• Cervical cancer cohort showed meaningful tumor shrinkage in previously treated recurrent or metastatic disease, including patients with prior immunotherapy.
• Safety profile was described as manageable across both cohorts, with no treatment-related deaths reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604132000PR_NEWS_USPR_____CN32458) on April 14, 2026, and is solely responsible for the information contained therein.